Brofaromine--a review of its pharmacological properties and therapeutic use.
The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances--brofaromine--will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.
Volz
H P
HP
Psychiatrische Klinik and Poliklinik Friedrich-Schiller-Universität Jena, Federal Republic of Germany.
Gleiter
C H
CH
Waldmeier
P C
PC
Struck
M
M
Möller
H J
HJ
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D010880:Piperidines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine